Stayble Therapeutics AB's CEO presents the company and the rights issue

In connection with the ongoing rights issue, Stayble Therapeutics CEO Andreas Gerward makes a number of presentations and interviews. More information about the rights issue, where the subscription period runs until 12 April, see https://www.foretradesemission.staybletherapeutics.se/.

Fill or Kill podcast, 28 March 2023. CEO Andreas Gerward participates in an interview in the podcast Fill or Kill. The episode is published via Swedish podcast applications and web services, such as Spotify, and can be heard on Stayble's website about the rights issue https://www.foretradesemission.staybletherapeutics.se/.

Investor meeting with Financial Stockholm, 29 March 2023 at 17:25-21:00. See the recorded presentation at the following link

Finwire CEO interview, Andreas Gerward is interviewed by Finwire. The interview will be available on April 3rd via the following link

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

E-mail: andreas.gerward@stayble.se

Phone: +46 (0) 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase 2b clinical trial in DDD and a Phase 1b trial in LDH.

Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Advisor.